65 results about "Pbsc mobilization" patented technology

Embodiments of the invention include compositions and methods related to engineered human mucosal-associated invariant T (eMAIT) cells for off-the-shelf use for clinical therapy for cancer, infectious, and autoimmune diseases. In some embodiments, the eMAIT cells are produced from healthy human donor peripheral blood, cord blood, or G-CSF mobilized peripheral blood. In particular embodiments, the eMAIT cells are produced from a pluripotent stem cell line and therefore can be of unlimited supply. In some embodiments, the eMAIT cells are engineered to express chimeric antigen receptors (CARs), or / and immune regulatory molecules, or / and allorejection resistance molecules. Embodiments of the invention also include compositions of matter comprising polynucleotides encoding mucosal-associated invariant T cell receptor alpha chain polypeptides and / or mucosal-associated invariant T cell receptor beta chain polypeptides.

A method for haematopoietic stem and / or progenitor cell (HSPC) transplantation in a subject in need thereof, comprising the steps: (a) administering one or more HSPC mobiliser to the subject to mobilise the subject's endogenous HSPCs; and (b) administering a population of HSPCs to the subject.

This invention relates to methods and compositions directed to mobilizing a cell in a subject by blocking CXCR4, a beta-adrenergic receptor, a GPCR, or any combination thereof. In some embodiments, the cell is a hematopoietic stem cell. In some embodiments, the method further comprises administration of G-CSF. This invention also relates to methods of treatment, methods for qualifying a subject for treatment, and methods for preparing a subject for treatment, by blocking CXCR4, a beta-adrenergic receptor, a GPCR, or any combination thereof. In some embodiments, the cell is a hematopoietic stem cell. In some embodiments, the treatment is for cancer. In some embodiments, the CXCR4 is GPC-100. In some embodiments, the method further comprises administration of G-CSF.

The invention discloses a system and a device for measuring the cardiopulmonary endurance of an adult, and relates to the technical field of cardiopulmonary endurance measurement. The system comprises a power vehicle, a heart rate acquisition module, a data processing module, a motion control and voice guide module, a load regulation and control module, a result output and data management module, a safety monitoring and stopping module and a user interaction module, and the power vehicle comprises a positioning base, a supporting seat, a vehicle frame, a counting and power utilization mechanism and a measurement and power recovery mechanism. A stable and controllable physical exercise platform and an adjustable load system are provided, a heart rate collection module collects heart rate data of a subject in the resting and exercise process in real time, and the heart rate data serve as a VOmax estimation core basis. And data of more dimensions can be incorporated during formula calculation of the maximum oxygen uptake, so that the effect is better.

To provide recombinant polyclonal proteins and use methods thereof.SOLUTION: Provided herein is a composition comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells or plasmablasts. Methods for using the RPPs are also provided. The RPPs are recombinant, and their sequences are derived from peripheral blood plasma cells or plasmablasts. The peripheral blood plasma cells or plasmablasts are mobilized by, e.g., a vaccine administered to a donor, and the peripheral blood plasma cells or plasmablasts are specifically separated from other peripheral blood cells. The peripheral blood cells can come from any mammal, for example a mouse, a rat, a human, a monkey, a horse, or a cow.SELECTED DRAWING: None

The invention discloses a small-molecule compound and application thereof in in-vitro amplification of hematopoietic stem cells and / or progenitor cells. The structural general formula of the small-molecule compound is as shown in formula (I). The series of compounds disclosed by the invention can be used in the medical field of related diseases taking hematopoietic stem cell transplantation as a treatment method, including in-vitro amplification culture of hematopoietic stem cells and progenitor cells from umbilical cord blood, bone marrow and mobilized peripheral blood and culture, maintenance and amplification of genetically modified hematopoietic stem and progenitor cells; meanwhile, the invention is suitable for application of downstream derived cell products generated by hematopoietic stem cell differentiation, including red blood cells, blood platelets, T cells, B cells and NK cells, in drugs for treating related diseases. # imgabs0 #

Aspects of the invention are drawn to compositions and methods for modulating CD8 Treg mobilization in the treatment of autoimmune disorders, rejection of transplanted organs and cancer.

Devices and methods for balloon delivery of rapamycin and other hydrophobic compounds to the wall of blood vessels. Balloon catheters, such as those used for stent deployment, are modified with the addition of a reservoir of dry micelles. The micelle preparation is reconstituted and the micelles are mobilized when the aqueous solution used to inflate the balloons is injected into the catheter. The micelles are infused into tissue surrounding the balloon when pressurized fluid within the balloon leaks through the wall of the balloon.

The present disclosure provides a soluble P-selectin (sP-sel) interfering the interaction between stem cells and niches to mobilize stem cells from bone marrow. The mobilization of stem cells with sP-sel can treat a subject in need of preservation, repair, or regeneration of a tissue, or revascularization.

The present invention relates to compositions comprising at least one monoclonal antibody directed against a protein expressed on hematopoietic stem cells for use in a method of providing stem cell engraftment in a subject. The invention also relates to such compositions for use in a method of treatment of hereditary anemias, bone marrow failures, immunodeficiencies and metabolic diseases. The method comprises at least one conditioning step comprising the simultaneous or subsequent administration of the composition comprising at least one monoclonal antibody directed against a protein expressed on hematopoietic stem cells and at least one hematopoietic stem cell mobilization agent to the subject.

The present invention provides a personalized rehabilitation training method and system based on state monitoring, which relates to the field of rehabilitation training technology. The method includes: obtaining electromyographic amplitude, root mean square, and spectrum median, calculating the rate of change, monitoring muscle fiber mobilization, blood oxygen, lactate metabolism, and heart rate variability, extracting the rate of change of joint angles and moment of inertia, and obtaining a training load reference value. In the present invention, by real-time monitoring and analysis of multiple physiological parameters including electromyographic signals, blood oxygen saturation, and heart rate variability, an accurate training load reference value is established to improve the accuracy of neuromuscular coordination assessment. By comparing the rate of change of electromyographic signals in short and long time windows, the training load is accurately adjusted to reduce fatigue risk. By real-time adjustment of the rehabilitation robot's motion trajectory and optimization of the training rhythm, it is ensured that the training intensity matches the individual's metabolic capacity, and dynamic matching and personalized adjustment of the training plan are achieved, effectively improving the safety and effectiveness of training.

The invention relates to an inhibitor of a histone acetyl transferase (HAT) activity of CREBBP(CBP) / p300 for use in the treatment of cytopenia. In embodiments, the inhibitor preferably suppresses a HAT domain of CBP / p300, more preferably by competing with acetyl CoA for binding to the HAT domain, thereby suppressing HAT enzymatic activity. In embodiments, the inhibitor induces acute and / or transient leukocytosis comprising mobilization of leukocytes from the bone marrow into the blood of a subject. The invention further relates to a pharmaceutical composition for use in the treatment of cytopenia, comprising the inhibitor according to the invention, and to a combination medication for use in the treatment of cytopenia, comprising the inhibitor according to the invention and a G-CSF or derivative thereof, preferably compound selected from G-CSF, recombinant G-CSF and / or G-CSF analogues.

Provided herein is a bioreactor system, including a cell growth platform having a hydrogel arranged thereon, at least one first cell received on and / or in the hydrogel, a flow channel configured to receive a flow of a liquid therethrough, a separator arranged between the cell growth platform and the flow channel and having a first surface that faces the cell growth platform and a second surface in fluid communication with the flow channel, and at least one second cell received on the separator.

The present invention relates to a combination therapy and combination product for mobilizing large numbers of hematopoietic stem cells in the blood, comprising substance P and AMD3100 or a pharmaceutically acceptable salt thereof; a method for collecting large numbers of mobilized hematopoietic stem cells, comprising a step of separating a blood fraction containing mobilized hematopoietic stem cells from peripheral blood obtained from an individual to whom substance P and AMD3100 or a pharmaceutically acceptable salt thereof have been sequentially administered; and the use of a formulation comprising substance P and AMD3100 or a pharmaceutically acceptable salt thereof for mobilizing large numbers of hematopoietic stem cells in the blood.

The present disclosure provides methods for treating various diseases or disorders, down-regulating and up-regulating various pathways and mobilizing stem and / or immune cells in a patient, comprising administering a pharmaceutical composition to a subject. In certain embodiments, the pharmaceutical composition comprises (a) a stem cell mobilizer and (b) an immunosuppressive agent or non-immunosuppressive FK binding protein ligand in a low or sub-immunosuppressive dose. The methods of the disclosure can comprise administering the pharmaceutical composition by routes and dosing regimens, as disclosed herein.

The present invention relates to a composition for preventing or treating Alzheimer's disease, comprising a phospholipase C (PLC) activator as an active ingredient. A composition comprising the PLC activator of the present invention as an active ingredient restores the S-eCB mobilization suppressed by AβO, recovers the synaptic plasticity impaired by AβO, and not only recovers PLCβ1 protein levels to normal levels in AβO-treated mouse hippocampal slices and 5XFAD mouse hippocampal slices in the chronic stage of AD, but also recovers contextual fear memory impairment in AD mice, and thus is expected to be usefully used for preventing or treating Alzheimer's disease.

Fibrinogen-coated Albumin Nanospheres (FAS) has shown that it can mobilize bone marrow cells into the blood which then go to injured soft and hard tissues to achieve accelerated repair. It is hypothesize that (a) brain injuries caused by low-dose irradiation under simulated microgravity can be mitigated by the administration of FAS; and (b) the mechanism is from acceleration of neo-vascularization, proven by lineage study of GFP-labeled bone marrow cells implanted into compatible non-GFP animals before injury, which regenerate into functional GFP-brain cells after FAS treatment.

The present invention relates to methods and compositions for mobilizing cells in a subject by blocking CXCR4, beta-adrenergic receptor, GPCR, or any combination thereof. In some embodiments, the cells are stem cells. In some embodiments, the cells are immune cells.

The present application relates to the field of biological medicine, in particular to a tumor treatment platform based on endogenous and exogenous zinc overload strategy, a preparation method and application. For the treatment platform, it comprises an acid-sensitive carrier, zinc ions and a sound-sensitive organic ligand; the sound-sensitive organic ligand can generate reactive oxygen under ultrasonic irradiation; the sound-sensitive organic ligand and the zinc ions are connected by a coordination bond to form a metal-organic complex; and the metal-organic complex is loaded on the acid-sensitive carrier. The present application proposes a tumor treatment strategy of "endogenous-exogenous synergy", combines "exogenous Zn 2+ " delivery with "endogenous Zn 2+ " mobilization, successfully induces "Zn 2+ overload" in cells through the synergistic effect of the two, realizes the precise, efficient and controllable induction of local Zn 2+ overload in tumors, and improves the effectiveness of pyroptosis. Through the present application, the limitations of traditional methods in controllability, efficacy and safety are overcome.

Disclosed herein are methods of mobilizing hematopoietic stem and progenitor cells (HSPC) in a subject in need thereof, the methods include administering one or both of (1) an inhibitor of the polymerization of hemoglobin S and (2) a P-selectin or E-selectin inhibitor, prior to administering a hematopoietic stem cell mobilizing agent.

A method of mobilizing hematopoietic precursor cells from the bone marrow to the peripheral blood of a subject is provided. The method comprising (a) administering to the subject an effective amount of natalizumab; and (b) administering to the subject an effective amount of a CXCR4 inhibitor, wherein step (b) is effected at least 48 hours following step (a). Also provided are uses of such mobilization procedures in cell collection and in treatment.

A method of mobilizing CD34 + cells in a subject suffering from sickle cell disease (SCD) is provided. The method comprises the following steps: a therapeutically effective amount of CXCR4 inhibitory peptide shown as SEQ ID NO: 1 and a therapeutically effective amount of natazumab are applied to a subject, and the natazumab and the CXCR4 inhibitory peptide are sequentially applied. Also provided is the use of mobilized cells for subsequent treatment of SCD in gene therapy.

Disclosed are devices, systems and methods for non-invasive neuromodulation system for treating inherited or acquired retinal, choroidal and optic nerve disorders caused by acute or chronic dysregulated reduced ocular blood flow (OBF) and / or energy failure by up regulation of trigemino-vascular system (TVS), trigeminal autonomic brain reflexes (TABRs) and pancreatic trigemino-vagal reflex (TVR) through stimulation of ophthalmic nerve (V1), more specifically but not limited to SP, and CGRP containing unmyelinated C nerve fibers. The invention, in some embodiments thereof, relates to the methods for enhancing SP and CGRP expression in neurovascular tissue of the retina and choroid. The invention, in some embodiments thereof, relates to SP / CGRP mediated pathways, including those involved in vasodilatation, augmentation of OBF, RPE proliferation, prevention of apoptosis, suppressing neuroinflammation, promoting migration and differentiation of vascular endothelial cells as well as mobilization of endogenous mesenchymal stem cells (EMSCs) from the bone marrow to the circulation to accelerate tissue repair. The site of stimulation of V1 nerve includes but not limited to; nasal vestibule nasal bridge, forehead, and upper eyelids. Additionally or alternatively, the subject's sympathetic nervous system (SNS) is down regulated by sympatholytic agents specifically antioxidants. The subject's TVS and autonomic nervous system (ANS) are modulated in a manner that is effective to treat the subject for retinal, choroidal and / or optic nerve disorders. In some embodiments, the devices are handheld, portable with nose supported, having one or more intra-nasal or extra-nasal application heads. The signal can include vibration, chemical, ultrasonic, optical, electrical, hybrid electro-optical or combination of two or more of these types of stimuli. The invention, in some embodiments thereof, relates to a method for decreasing vascular resistance, enhancing vasodilatation in ophthalmic artery and its branches by the release of Vasoactive intestinal peptide (VIP), substance P and CGRP thereof increasing OBF to the retina, choroid and optic nerve in subject's with acute or chronic dysregulated, reduced OBF. The invention, in some embodiments thereof, is also relates to the methods for improving delivery of oxygen, glucose, vitamin A, humoral mediators, growth factors, stem cells and pharmacological agents to the targeted tissues of the retina, choroid and optic nerve. The invention, in some embodiments thereof, relates to the methods for improving pancreatic insulin secretion, thereof to enhance glucose uptake by PRs and other retinal cells. Additionally or alternatively, the invention relates to restoration of transduction of signaling in cone PRs by ONS induced glutamate release. The methods of the invention, in some embodiments thereof, include priming of the retina choroid and optic nerve thereof to enhance the efficacy of cell transplantation therapy. The methods of the invention, in some embodiments thereof, also include identifying a subject prone to or suffering from a disease or condition associated with reduced OBF. Methods of the invention, in some embodiments thereof, may also include monitoring the subject for prophylactic treatment where the patients are at pre-clinical stage of the disease. The OBF of subjects who had received neuromodulation treatment may also be monitored for re-treatment.The present invention, in some embodiments thereof, relates to a method and / or device for treatment of dysregulated reduced blood (e.g. reduced ocular blood flow) and, more particularly, but not exclusively, to methods and / or devices for treatment retinal, choroidal and optic nerve disorders. Optionally, treatment may include application of an effective amount of ONS ophthalmic nerve stimulation alone and / or in combination with peri-ocular administration of substance Neuropeptides / Platelet Rich Plasma (N / PRP) and / or ascorbic acid as a sympatholytic agent

Means, methods, and compositions of matter for accelerating hematopoiesis and / or stem cell engraftment through induction of senolysis and / or deactivation of senescent cells. Senolytic agents can be administered together with hematopoietic growth factors. Resistance to stem cell mobilization can be accomplished by removal of senescent cells through senolytic and / or senescence inactivating approaches.

This invention relates to methods for treatment of diseases of aging including immunosenescence, immune dysfunction, inflammation and impairment of early lymphoid lineage differentiation. The invention more specifically relates to the use of granulocyte colony stimulating factors to assist in stem cell mobilization, optionally in combination with the application of a method of delivering precise magnetic field patterns which agree with the body's own natural magnetic field patterns, and further in combination with re-infusion of previously collected autologous cells and / or plasma, optionally including allogeneic (healthy donor) cells and blood plasma.

The invention belongs to the technical field of biological medicines, and particularly relates to a pharmaceutical composition for treating thalassemia and application thereof. The invention provides a pharmaceutical composition for treating thalassemia, which comprises: (a) a cell population containing a first type of cells and a second type of cells, the cell population can be used for differentiating to generate red blood cells, target loci of the first type of cells are edited to increase red blood cells expressing functional hemoglobin generated by differentiation of the cell population, and target loci of the second type of cells are edited to generate target loci of the second type of cells; the target gene loci of the second type of cells are not edited; (b) a mobilizing agent. The medicine composition can achieve the effect of treating thalassemia through cell transplantation without removing marrow, and the clinical treatment risk of a patient is reduced.

The invention designs a novel double-target peptide agonist targeting peripheral Kappa and Mu opioid receptors or pharmaceutically acceptable salts of the double-target peptide agonist, namely, chimeric peptides MKOP001 and MKOP002 are newly constructed on the basis of a DN-9 and dynorphin efficient analogue [des-Arg7] Dyn A (1-11)-NH2 sequence. An in-vitro calcium mobilization experiment and an acute analgesic experiment show that the brand new peptide agonists MKOP001 and MKOP002 can simultaneously activate Kappa and Mu opioid receptors and generate efficient analgesic activity. In addition, further research shows that both the MKOP001 and the MKOP002 can generate a remarkable itching relieving effect. Therefore, the peripheral restrictive Kappa and Mu opioid receptor double-target peptide molecules MKOP001 and MKOP002 or pharmaceutically acceptable salts thereof have very high application value in the aspect of preparing high-efficiency and low-side-effect analgesic or antipruritic drugs.

The present disclosure provides methods for treating various diseases or disorders, down-regulating and up-regulating various pathways and mobilizing stem and / or immune cells in a patient, comprising administering a pharmaceutical composition to a subject. In certain embodiments, the pharmaceutical composition comprises (a) a stem cell mobilizer and (b) an immunosuppressive agent or non-immunosuppressive FK binding protein ligand in a low or sub-immunosuppressive dose. The methods of the disclosure can comprise administering the pharmaceutical composition by routes and dosing regimens, as disclosed herein.

The present invention relates to methods and compositions for mobilizing cells in a subject by blocking CXCR4, β-adrenergic receptors, GPCRs, or any combination thereof. In some embodiments, the cells are stem cells. In some embodiments, the cells are immune cells.

This invention relates to methods for treatment of diseases of aging including immunosenescence, immune dysfunction, inflammation and impairment of early lymphoid lineage differentiation. The invention more specifically relates to the use of granulocyte colony stimulating factors to assist in stem cell mobilization, optionally in combination with the application of a method of delivering precise magnetic field patterns which agree with the body's own natural magnetic field patterns, and further in combination with re-infusion of previously collected autologous cells and / or plasma, optionally including allogeneic (healthy donor) cells and blood plasma.